Is HBV prophylaxis required during CLL treatment with ibrutinib? - Wikidata - wikimedia - TriplyDB

Is HBV prophylaxis required during CLL treatment with ibrutinib?

Is HBV prophylaxis required during CLL treatment with ibrutinib?

http://www.wikidata.org/entity/Q54653633

about

Is HBV prophylaxis required during CLL treatment with ibrutinib?

http://www.wikidata.org/entity/Q54653633

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Is HBV prophylaxis required during CLL treatment with ibrutinib?

@en

Is HBV prophylaxis required during CLL treatment with ibrutinib?

@nl

type

label

Is HBV prophylaxis required during CLL treatment with ibrutinib?

@en

Is HBV prophylaxis required during CLL treatment with ibrutinib?

@nl

prefLabel

Is HBV prophylaxis required during CLL treatment with ibrutinib?

@en

Is HBV prophylaxis required during CLL treatment with ibrutinib?

@nl

P1433

Q54653633-A197F9F3-811F-4771-8D64-F1FCC6407362

P1476

Q54653633-31568575-B0F6-48BD-A7D1-6A90DEC5B6F8

P2093

Q54653633-6BC4EA2A-3759-45F4-81B5-5DDCF4FE87C8

Q54653633-B11F8A90-2D24-4307-B580-716E9B013FBB

Q54653633-B71CF630-24BF-496E-B3F3-D2DAF05A726B

Q54653633-D5D66E31-0749-401B-87F3-ADEA813B42B3

Q54653633-F652A5C1-0817-450C-BEB6-0BA87E57A943

P2860

Q54653633-099DBA7F-6EAB-4024-906A-B2C2F5ACAC63

Q54653633-2D33B6BD-1AC8-40A7-B5CB-D8C5978D0D74

Q54653633-2E250443-6C76-474E-817B-2284DDD89C03

Q54653633-304069E1-88E7-43A2-AE1E-2F3D26BF9C2E

Q54653633-5B8B634C-6049-4F14-98D4-FA39ACBA0997

Q54653633-5C06C550-0E0E-4945-8CF8-FDB86489FFD8

Q54653633-73D726D8-EAEC-4284-8302-251D64AF3812

Q54653633-772F65EC-8AFA-4BD6-A9F3-4154A7A5A92E

Q54653633-88B1D55D-6C63-448E-8430-A81865369843

Q54653633-B6BE4AF6-B82B-4223-B0DC-2DEE204A6DAC

P304

Q54653633-C156010C-A2E2-438F-9736-858FB591FF37

P31

Q54653633-30270C4E-39F5-4719-B98D-562EDA236103

P356

Q54653633-DB436C8B-42FA-4C7E-B00D-52AF781F4965

P433

Q54653633-F151EDFA-6F45-490F-B3F5-0E6467DCFC17

P478

Q54653633-8399A3A6-244D-4399-B234-945A06A839FD

P577

Q54653633-EC214B4B-C685-4FE7-B5A7-B0931768278E

P698

Q54653633-BEEDC647-76A2-493D-A015-1E64450DB095

P356

10428194.2017.1317094

P1433

Leukemia & Lymphoma

P1476

Is HBV prophylaxis required during CLL treatment with ibrutinib?

@en

P2093

Alessandra Tedeschi

http://www.w3.org/2001/XMLSchema#string

Anna Maria Frustaci

http://www.w3.org/2001/XMLSchema#string

Maddalena Mazzucchelli

http://www.w3.org/2001/XMLSchema#string

Marco Montillo

http://www.w3.org/2001/XMLSchema#string

Roberto Cairoli

http://www.w3.org/2001/XMLSchema#string

P2860

JAKs and STATs in immunity, immunodeficiency, and cancer.

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review.

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).

Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib.

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.

P304

2966-2968

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1317094

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28535112

http://www.w3.org/2001/XMLSchema#string